Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells

Biomaterials

Volumn 72, Issue , 2015, Pages 74-89

  Wang, Hai ^a,b,c   Agarwal, Pranay ^a,b   Zhao, Shuting ^a,b   Xu, Ronald X ^a,c   Yu, Jianhua ^c,d   Lu, Xiongbin ^e   He, Xiaoming ^a,b,c  

^a Ohio State University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer stem like cell; CD44; Co delivery; Drug resistance; Topoisomerase

Indexed keywords

CELL DEATH; CHITOSAN; CONTROLLED DRUG DELIVERY; DISEASES; DRUG PRODUCTS; EMULSIFICATION; FUNCTIONAL POLYMERS; HYALURONIC ACID; NANOPARTICLES; ORGANIC ACIDS; POLYVINYL ALCOHOLS; SYNTHESIS (CHEMICAL);

CD44; CO DELIVERIES; DOXORUBICIN HYDROCHLORIDE; DRUG RESISTANCE; FOOD AND DRUG ADMINISTRATION; POLY(D ,L-LACTIDE-CO-GLYCOLIDE); TOPOISOMERASES; TRIGGERED DRUG RELEASE;

TARGETED DRUG DELIVERY;

CHITOSAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; HYALURONIC ACID; IRINOTECAN; NANOPARTICLE; POLOXAMER; POLYGLACTIN; POLYVINYL ALCOHOL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DNA REPAIR; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; EMULSION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG RESISTANCE; ENDOCYTOSIS; INTRACELLULAR SPACE; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; PH; TISSUE DISTRIBUTION; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CHITOSAN; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; HYALURONIC ACID; HYDROGEN-ION CONCENTRATION; INTRACELLULAR SPACE; LACTIC ACID; MALE; MICE, NUDE; NANOPARTICLES; NEOPLASTIC STEM CELLS; POLOXAMER; POLYGLYCOLIC ACID; SPHEROIDS, CELLULAR; TISSUE DISTRIBUTION;

EID: 84943243848     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.08.048     Document Type: Article

References (48)

1. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N. Engl. J. Med. 2006, 355:1253-1261.
2. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
3. Gilbert C.A., Ross A.H. Cancer stem cells: cell culture, markers, and targets for new therapies. J. Cell Biochem. 2009, 108:1031-1038.
4. Chin A.R., Wang S.E. Cytokines driving breast cancer stemness. Mol. Cell Endocrinol. 2014, 382:598-602.
5. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 2011, 121:3804-3809.
6. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
7. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
8. Zeng X., Morgenstern R., Nystrom A.M. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance. Biomaterials 2014, 35:1227-1239.
9. Hu C.M., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83:1104-1111.
10. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
11. El-Dakdouki M.H., Xia J., Zhu D.C., Kavunja H., Grieshaber J., O'Reilly S., et al. Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles. ACS Appl. Mater. Interfaces 2014, 6:697-705.
12. Mo R., Jiang T., DiSanto R., Tai W., Gu Z. ATP-triggered anticancer drug delivery. Nat. Commun. 2014, 5:3364.
13. Ruiz-Esparza G.U., Wu S., Segura-Ibarra V., Cara F.E., Evans K.W., Milosevic M., et al. polymer nanoparticles encased in a cyclodextrin complex shell for potential site - and sequence - specific drug release. Adv. Funct. Mater 2014, 24:4753-4761.
14. Cheng R., Meng F.H., Deng C., Klok H.A., Zhong Z.Y. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013, 34:3647-3657.
15. Bertrand N., Wu J., Xu X.Y., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66:2-25.
16. Koval M., Preiter K., Adles C., Stahl P.D., Steinberg T.H. Size of IgG-opsonized particles determines macrophage response during internalization. Exp. Cell Res. 1998, 242:265-273.
17. Sahoo S.K., Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm. 2005, 2:373-383.
18. Albanese A., Walkey C.D., Olsen J.B., Guo H., Emili A., Chan W.C. Secreted biomolecules alter the biological identity and cellular interactions of nanoparticles. ACS Nano 2014, 8:5515-5526.
19. Holohan C., Van Schaeybroeck S., Longley D.B., Johnston P.G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 2013, 13:714-726.
20. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
21. Hirose S., Suzuki Y. In vitro transcription of eukaryotic genes is affected differently by the degree of DNA supercoiling. Proc. Natl. Acad. Sci. 1988, 85:718-722.
22. Liu L.F., Wang J.C. Supercoiling of the DNA template during transcription. Proc. Natl. Acad. Sci. 1987, 84:7024-7027.
23. Hu C.M., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 2010, 1:323-334.
24. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44 (+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
25. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N. Engl. J. Med. 2006, 355:1253-1261.
26. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine 2012, 7:597-615.
27. Zhang W., Gilstrap K., Wu L., R K.C., Moss M.A., Wang Q., et al. Synthesis and characterization of thermally responsive Pluronic F127-chitosan nanocapsules for controlled release and intracellular delivery of small molecules. ACS nano 2010, 4:6747-6759.
28. Rao W., Zhang W., Poventud-Fuentes I., Wang Y., Lei Y., Agarwal P., et al. Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction. Acta Biomater. 2014, 10:831-842.
29. Zhang W., Rong J., Wang Q., He X. The encapsulation and intracellular delivery of trehalose using a thermally responsive nanocapsule. Nanotechnology 2009, 20:275101.
30. Wang H., Zhao Y., Wu Y., Hu Y.L., Nan K., Nie G., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32:8281-8290.
31. Rao W., Bellotti A., Littrup P.J., Yu J., Lu X., He X. Nanoparticle-encapsulated doxorubicin enhances cryoablation of cancer stem-like cells. Technology 2014, 2:28-35.
32. Rao W., Zhao S., Yu J., Lu X., Zynger D.L., He X. Enhanced enrichment of prostate cancer stem-like cells with miniaturized 3D culture in liquid core-hydrogel shell microcapsules. Biomaterials 2014, 35:7762-7773.
33. Pommier Y., Leo E., Zhang H., Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17:421-433.
34. Nishimura S., Tsuda H., Hashiguchi Y., Kokawa K., Nishimura R., Ishiko O., et al. Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2007, 17:159-163.
35. Cortes F., Pinero J. Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells. Cancer Chemother. Pharmacol. 1994, 34:411-415.
36. Kim R., Hirabayashi N., Nishiyama M., Jinushi K., Toge T., Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer 1992, 50:760-766.
37. Jen M.C., Serrano M.C., van Lith R., Ameer G.A. Polymer - based nitric oxide therapies: recent insights for biomedical applications. Adv. Funct. Mater 2012, 22:239-260.
38. Sun T., Zhang Y.S., Pang B., Hyun D.C., Yang M., Xia Y. Engineered Nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 2014, 53:12320-12364.
39. Wang H., Zhao Y., Wu Y., Y-l Hu, Nan K., Nie G., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32:8281-8290.
40. Su S., Wang H., Liu X., Wu Y., Nie G. iRGD-coupled responsive fluorescent nanogel for targeted drug delivery. Biomaterials 2013, 34:3523-3533.
41. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9469-9474.
42. Rao W., Wang H., Han J., Zhao S., Dumbleton J., Agarwal P., et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 2015, 9:5725-5740.
43. Gardner S.N. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Cancer Res. 2000, 60:1417-1425.
44. Xu Y., Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. Off. J. Eur. Soc. Med. Onco. ESMO 2002, 13:1841-1851.
45. Marhaba R., Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J. Mol. Histol. 2004, 35:211-231.
46. Sahlberg S.H., Spiegelberg D., Glimelius B., Stenerlöw B., Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PloS One 2014, 9:e94621.
47. Meyer K.N., Kjeldsen E., Straub T., Knudsen B.R., Hickson I.D., Kikuchi A., et al. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J. Cell Biol. 1997, 136:775-788.
48. Wang J.C., Caron P.R., Kim R.A. The role of DNA topoisomerases in recombination and genome stability: a double-edged sword?. Cell 1990, 62:403-406.